Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 161

1.

Episodes of low-level viral rebound in HIV-infected patients on antiretroviral therapy: frequency, predictors and outcome.

García-Gascó P, Maida I, Blanco F, Barreiro P, Martín-Carbonero L, Vispo E, González-Lahoz J, Soriano V.

J Antimicrob Chemother. 2008 Mar;61(3):699-704. doi: 10.1093/jac/dkm516. Epub 2008 Jan 12.

PMID:
18192682
2.

Long-term virological outcome and resistance mutations at virological rebound in HIV-infected adults on protease inhibitor-sparing highly active antiretroviral therapy.

de la Rosa R, Ruíz-Mateos E, Rubio A, Abad MA, Vallejo A, Rivero L, Genebat M, Sánchez-Quijano A, Lissen E, Leal M.

J Antimicrob Chemother. 2004 Jan;53(1):95-101. Epub 2003 Dec 4.

PMID:
14657091
3.

Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy.

Geretti AM, Smith C, Haberl A, Garcia-Diaz A, Nebbia G, Johnson M, Phillips A, Staszewski S.

Antivir Ther. 2008;13(7):927-36.

PMID:
19043927
4.

Persistent low-level viraemia and virological failure in HIV-1-infected patients treated with highly active antiretroviral therapy.

Sungkanuparph S, Groger RK, Overton ET, Fraser VJ, Powderly WG.

HIV Med. 2006 Oct;7(7):437-41.

5.

Detection of drug resistance mutations as a predictor of subsequent virological failure in patients with HIV-1 viral rebounds of less than 1,000 RNA copies/ml.

Verhofstede C, Van Wanzeele F, Van Der Gucht B, Pelgrom J, Vandekerckhove L, Plum J, Vogelaers D.

J Med Virol. 2007 Sep;79(9):1254-60.

PMID:
17607772
6.

Oral lesions as clinical markers of highly active antiretroviral therapy failure: a nested case-control study in Mexico City.

Ramírez-Amador V, Ponce-de-León S, Anaya-Saavedra G, Crabtree Ramírez B, Sierra-Madero J.

Clin Infect Dis. 2007 Oct 1;45(7):925-32. Epub 2007 Aug 23.

PMID:
17806063
7.

Residual viraemia in subjects with chronic HIV infection and viral load < 50 copies/ml: the impact of highly active antiretroviral therapy.

Palmisano L, Giuliano M, Nicastri E, Pirillo MF, Andreotti M, Galluzzo CM, Bucciardini R, Fragola V, Andreoni M, Vella S.

AIDS. 2005 Nov 4;19(16):1843-7.

PMID:
16227792
8.

Increased risk of early virological failure in non-European HIV-1-infected patients in a Dutch cohort on highly active antiretroviral therapy.

van den Berg JB, Hak E, Vervoort SC, Hoepelman IM, Boucher CA, Schuurman R, Schneider MM.

HIV Med. 2005 Sep;6(5):299-306.

9.

Lopinavir/ritonavir monotherapy as maintenance treatment in HIV-infected individuals with virological suppression: results from a pilot study in Brazil.

Sprinz E, Bay MB, Lazzaretti RK, Jeffman MW, Mattevi VS.

HIV Med. 2008 May;9(5):270-6. doi: 10.1111/j.1468-1293.2008.00558.x. Epub 2008 Mar 10.

10.

Transient relapses ("blips") of plasma HIV RNA levels during HAART are associated with drug resistance.

Cohen Stuart JW, Wensing AM, Kovacs C, Righart M, de Jong D, Kaye S, Schuurman R, Visser CJ, Boucher CA.

J Acquir Immune Defic Syndr. 2001 Oct 1;28(2):105-13.

PMID:
11588503
11.

Predictors of successful genotype-guided antiretroviral therapy in treatment-experienced individuals over calendar years: a cohort study.

Bracciale L, Fanti I, Di Giambenedetto S, Colafigli M, Prosperi M, Bacarelli A, Santangelo R, Cattani P, Cauda R, De Luca A.

J Clin Virol. 2009 Nov;46(3):290-4. doi: 10.1016/j.jcv.2009.07.013. Epub 2009 Aug 21.

PMID:
19699675
12.

Virological and immunological profiles among patients with undetectable viral load followed prospectively for 24 months.

Katzenstein TL, Ullum H, Røge BT, Wandall J, Dickmeiss E, Barrington T, Skinhøj P, Gerstoft J.

HIV Med. 2003 Jan;4(1):53-61.

13.

Raised viral load in patients with viral suppression on highly active antiretroviral therapy: transient increase or treatment failure?

Moore AL, Youle M, Lipman M, Cozzi-Lepri A, Lampe F, Madge S, Nesaratnam S, Tyrer M, Cuthbertson Z, Ransom D, Loveday C, Johnson MA, Phillips AN; Royal Free Centre for HIV Medicine.

AIDS. 2002 Mar 8;16(4):615-8.

PMID:
11873005
14.

Transient rebounds of HIV plasma viremia are associated with the emergence of drug resistance mutations in patients on highly active antiretroviral therapy.

Macias J, Palomares JC, Mira JA, Torres MJ, García-García JA, Rodríquez JM, Vergera S, Pineda JA.

J Infect. 2005 Oct;51(3):195-200. Epub 2005 Jan 12.

PMID:
16230215
15.

Improved virological response to highly active antiretroviral therapy in HIV-1-infected patients carrying the CCR5 Delta32 deletion.

Laurichesse JJ, Persoz A, Theodorou I, Rouzioux C, Delfraissy JF, Meyer L.

HIV Med. 2007 May;8(4):213-9.

16.

Use of viral load measured after 4 weeks of highly active antiretroviral therapy to predict virologic outcome at 24 weeks for HIV-1-positive individuals.

Smith CJ, Staszewski S, Sabin CA, Nelson M, Dauer B, Gute P, Johnson MA, Phillips AN, Gazzard B.

J Acquir Immune Defic Syndr. 2004 Sep 1;37(1):1155-9.

PMID:
15319675
17.

Genetic evolution of HIV in patients remaining on a stable HAART regimen despite insufficient viral suppression.

Kristiansen TB, Pedersen AG, Eugen-Olsen J, Katzenstein TL, Lundgren JD.

Scand J Infect Dis. 2005;37(11-12):890-901.

PMID:
16308226
18.

Effect of suppressing HIV viremia on the HIV progression of patients undergoing a genotype resistance test after treatment failure.

Zaccarelli M, Lorenzini P, Tozzi V, Forbici F, Ceccherini-Silberstein F, Gori C, D'Arrigo R, Trotta MP, Narciso P, Perno CF, Antinori A; Collaborative Group for Clinical Use of the HIV Genotype Resistance Test (GRT) at the National Institute for Infectious Diseases "Lazzaro Spallanzani".

Infection. 2009 Jun;37(3):203-9. doi: 10.1007/s15010-008-8142-8. Epub 2009 Mar 9.

PMID:
19274429
19.

Significant link between sCD30 changes and HIV viremia in patients treated with HAART.

Biswas P, Cozzi-Lepri A, Delfanti F, Galli A, Colangeli V, Moioli MC, Scarchilli A, Abrescia N, Vigevani G, D'Arminio-Monforte A, Novati R, Lazzarin A.

J Med Virol. 2006 Dec;78(12):1513-9.

PMID:
17063513
20.

Response to HAART in French patients with resistant HIV-1 treated at primary infection: ANRS Resistance Network.

Chaix ML, Desquilbet L, Descamps D, Costagliola D, Deveau C, Galimand J, Goujard C, Signori-Schmuck A, Schneider V, Tamalet C, Pellegrin I, Wirden M, Masquelier B, Brun-Vezinet F, Rouzioux C, Meyer L; French PRIMO Cohort Study Group (ANRS CO 06); French ANRS AC11 Resistance Study Group.

Antivir Ther. 2007;12(8):1305-10.

PMID:
18240870

Supplemental Content

Support Center